Literature DB >> 28639700

Systematic review: health-related quality of life in children and adults with eosinophilic oesophagitis-instruments for measurement and determinant factors.

A J Lucendo1,2, L Arias-González1,2, J Molina-Infante2,3, Á Arias2,4.   

Abstract

BACKGROUND: Several measures have been used to assess the health-related quality of life (HRQoL) of patients with eosinophilic oesophagitis (EoE). AIMS: To systematically review these HRQoL measures, to appraise measurement properties of specific instruments and to evaluate determinant factors influencing HRQoL in paediatric and adult EoE patients.
METHODS: We searched the PubMed, Embase, Scopus, Web of Science (WOS) and PsycINFO databases for documents providing original information on the development of measurement tools and/or evaluation of HRQoL outcomes in EoE patients of all ages.
RESULTS: Of the 596 references identified, data was collected from 34 studies (with only 16 of them being published as full papers) including a total of 1,689 individual patients. Three disease-specific HRQoL measures in EoE covering different aspects of patients' lives and developed in English, were scored positive regarding measurement properties. The PedsQL inventory (including parent and child report forms) and the Peds-QoL EoE module were the generic and specific instruments respectively used in children, while the SF-36 and EoE-QoL-A were the most used questionnaires in adults. Patients with EoE show an impaired HRQoL compared to controls, which greatly depends on symptom severity and disease duration. Severity of endoscopic features and female gender may also determine an impaired HRQoL. The effect of treatments on HRQoL requires further assessment.
CONCLUSIONS: HRQoL is a relevant outcome that should be considered in clinical practice and research of EoE. Further validation studies in several languages and populations are required to support the use of disease-specific HRQoL measures.
© 2017 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2017        PMID: 28639700     DOI: 10.1111/apt.14194

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  10 in total

1.  British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults.

Authors:  Anjan Dhar; Hasan N Haboubi; Stephen E Attwood; Marcus K H Auth; Jason M Dunn; Rami Sweis; Danielle Morris; Jenny Epstein; Marco R Novelli; Hannah Hunter; Amanda Cordell; Sharon Hall; Jamal O Hayat; Kapil Kapur; Andrew Robert Moore; Carol Read; Sarmed S Sami; Paul J Turner; Nigel J Trudgill
Journal:  Gut       Date:  2022-05-23       Impact factor: 31.793

2.  Clinical spectrum of paediatric and adult eosinophilic oesophagitis in the North East of England from 2016 to 2019.

Authors:  Ben Shillitoe; Ji Ching Lee; Mohammed Hussien; Iosif Beintaris; Mark Stothard; Matthew Johnston; Helen Jane Dallal; Louise J Michaelis; Stephen Attwood; Anjan Dhar
Journal:  Frontline Gastroenterol       Date:  2021-06-08

Review 3.  Treatment of eosinophilic esophagitis in the pediatric patient: an evidence-based approach.

Authors:  Mery Munoz-Persy; Alfredo J Lucendo
Journal:  Eur J Pediatr       Date:  2018-03-17       Impact factor: 3.183

4.  Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6-week open-label trial of the EOS-2 Programme.

Authors:  Stephan Miehlke; Christoph Schlag; Alfredo J Lucendo; Luc Biedermann; Cecilio Santander Vaquero; Christoph Schmoecker; Jamal Hayat; Petr Hruz; Constanza Ciriza de Los Rios; Albert Jan Bredenoord; Michael Vieth; Alain Schoepfer; Stephen Attwood; Ralph Mueller; Sarah Burrack; Roland Greinwald; Alex Straumann
Journal:  United European Gastroenterol J       Date:  2022-04       Impact factor: 4.623

Review 5.  Eosinophilic esophagitis in children: doubts and future perspectives.

Authors:  Elena Cavalli; Andrea Brusaferro; Elena Sofia Pieri; Rita Cozzali; Edoardo Farinelli; Gian Luigi De' Angelis; Susanna Esposito
Journal:  J Transl Med       Date:  2019-08-09       Impact factor: 5.531

6.  EoE CONNECT, the European Registry of Clinical, Environmental, and Genetic Determinants in Eosinophilic Esophagitis: rationale, design, and study protocol of a large-scale epidemiological study in Europe.

Authors:  Alfredo J Lucendo; Cecilio Santander; Edoardo Savarino; Danila Guagnozzi; Isabel Pérez-Martínez; Antonia Perelló; Antonio Guardiola-Arévalo; Jesús Barrio; María Elena Betoré-Glaria; Carolina Gutiérrez-Junquera; Constanza Ciriza de Los Ríos; Francesca Racca; Sonia Fernández-Fernández; Leonardo Blas-Jhon; Anne Lund Krarup; Susana de la Riva; Juan E Naves; Silvia Carrión; Juan Armando Rodríguez Oballe; Natalia García-Morales; Sonsoles Tamarit-Sebastián; Pilar Navarro; Ángel Arias; Emilio J Laserna-Mendieta
Journal:  Therap Adv Gastroenterol       Date:  2022-02-02       Impact factor: 4.409

Review 7.  A meta-analysis on randomized controlled trials of treating eosinophilic esophagitis with budesonide.

Authors:  Xiaopei Liu; Xue Xiao; Dan Liu; Cong'e Tan
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

Review 8.  Dietary Management of Eosinophilic Esophagitis: Tailoring the Approach.

Authors:  Pierfrancesco Visaggi; Lucia Mariani; Veronica Pardi; Emma Maria Rosi; Camilla Pugno; Massimo Bellini; Fabiana Zingone; Matteo Ghisa; Elisa Marabotto; Edoardo G Giannini; Vincenzo Savarino; Santino Marchi; Edoardo V Savarino; Nicola de Bortoli
Journal:  Nutrients       Date:  2021-05-12       Impact factor: 5.717

Review 9.  Treatment of eosinophlic esophagitis with swallowed topical corticosteroids.

Authors:  Simon Nennstiel; Christoph Schlag
Journal:  World J Gastroenterol       Date:  2020-09-28       Impact factor: 5.742

Review 10.  Evidence-based treatments for eosinophilic esophagitis: insights for the clinician.

Authors:  Sara Feo-Ortega; Alfredo J Lucendo
Journal:  Therap Adv Gastroenterol       Date:  2022-01-19       Impact factor: 4.409

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.